ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
124.851,42
-0,24%
S&P 500
5.068,39
-0,04%
US Dollar vs BRL
5,1511
0,37%
Bitcoin
64.243,65
-3,26%
Brent Oil
87,32
-0,28%
Registration Strip Icon for discussion Cadastre-se para interagir em nossos fóruns de ativos e discutir com investidores ideias semelhantes.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NYSE
  6. Merck and Co Inc (MRK)

  7. Merck and Co Inc (MRK) Notícias

MRK Merck and Co Inc

127,25
0,37 (0,29%)
Última atualização: 16:05:29
Atrasado em 15 minutos
Nome da Ação Código da Ação Bolsa de Valores Tipo de Ativo
Merck and Co Inc MRK NYSE Ordinária
  Variação do Dia (p) Variação do Dia % Último Preço Hora
Upgrade Icon
0,37 0,29% 127,25 16:05:29
Preço de Abertura Preço Mínimo Preço Máximo Fech. Hoje Fech. Anterior
126,815 125,35 127,40 126,88
mais cotações »

Notícias Recentes

Data Hora Fonte Título
19/04/202408:04PRNCAHealth Canada Approves KEYTRUDA® as a first-line treatment..
10/04/202408:13IHMARKETNEWSDelta Generates US$37 Million Profit in Q1, Google and Intel..
04/04/202407:45BWMerck Initiates Phase 3 Clinical Trial of MK-1084, an..
03/04/202409:00BWREJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan..
01/04/202407:45BWMerck to Hold First-Quarter 2024 Sales and Earnings..
28/03/202407:45BWEuropean Commission Approves Merck’s KEYTRUDA®..
27/03/202407:54IHMARKETNEWSGameStop Shares Tumble 20% in Pre-Market Trading Amid..
26/03/202419:21BWFDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a..
21/03/202407:45BWMerck Provides Update on Phase 3 KEYLYNK-006 Trial..
19/03/202410:00BWMerck Announces Positive Data on V116, an Investigational,..
15/03/202417:23PRNUSFarmSee Ltd Announces the Completion of a Minority..
15/03/202407:45BWMerck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy..
13/03/202404:00BWMerck Announces Plans to Conduct Clinical Trials of a Novel..
11/03/202409:15BWMerck Completes Acquisition of Harpoon Therapeutics, Inc.
06/03/202412:25BWGilead and Merck Announce Phase 2 Data Showing an..
05/03/202411:03IHMARKETNEWSFutures Pointing To Continued Weakness On Wall Street
05/03/202408:45BWMerck to Participate in the Barclays 26th Annual Global..
04/03/202408:45BWMerck to Participate in the Leerink Partners Global..
27/02/202408:45BWMerck to Participate in the TD Cowen 44th Annual Health Care..
23/02/202408:20BWMerck Receives Positive EU CHMP Opinion for KEYTRUDA®..
20/02/202408:45BWFDA Grants Priority Review to Merck's Application for..
12/02/202409:05PRNCAHealth Canada Approves KEYTRUDA® in combination with..
08/02/202409:00PRNCAMERCK CANADA ANNONCE UNE COLLABORATION AVEC L'INSTITUT..
05/02/202408:33BWMerck Animal Health to Acquire Elanco’s Aqua Business
01/02/202408:30BWMerck Announces Fourth-Quarter and Full-Year 2023 Financial..
27/01/202412:00BWMerck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Death..
26/01/202412:00BWMerck’s KEYTRUDA® (pembrolizumab) Significantly Improved..
25/01/202410:07DJNLava Therapeutics Shares Rise as Drug Set for Test With..
23/01/202416:44BWMerck Announces Second-Quarter 2024 Dividend
23/01/202408:05DJNSanofi to Buy Assets From Inhibrx in Deal Valued at Up to..
19/01/202408:45BWMerck to Hold Fourth-Quarter and Full-Year 2023 Sales and..
15/01/202410:15PRNUSMerck Animal Health's Fourth Veterinary Wellbeing Study..
12/01/202420:13DJNMerck's Keytruda Combined with Chemoradiotherapy Gets FDA..
12/01/202419:30BWFDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus..
09/01/202412:21DJNMerck on Track for Record High Close -- Data Talk
09/01/202408:12IHMARKETNEWSWall Street Highlights: HPE and Juniper Networks in..
08/01/202416:54DJNTrending: Johnson & Johnson and Merck & Co. Announce..
08/01/202410:45IHNWExciting New Cures Possible from GLP-1 Diabetes, Weight-Loss..
08/01/202410:12DJNMerck to Buy Harpoon Therapeutics for $680 Million
08/01/202409:30BWMerck to Acquire Harpoon Therapeutics, Further Diversifying..
08/01/202408:47DJNHarpoon Therapeutics Shares Take Flight Premarket on Report..
05/01/202408:45BWMerck Announces Phase 3 Trial Initiations for Four..
03/01/202408:45BWMerck to Participate in the 42nd Annual J.P. Morgan..
22/12/202310:00BWPatritumab Deruxtecan Granted Priority Review in the U.S...
21/12/202309:05PRNCAKEYTRUDA® (pembrolizumab) en association avec LENVIMA®..
20/12/202319:27DJNFDA Says Merck's Chronic Cough Treatment Didn't Show..
20/12/202318:30BWMerck Provides U.S. Regulatory Update on Gefapixant
20/12/202308:45BWMerck to Participate in the Goldman Sachs Healthcare C-Suite..
19/12/202309:29DJNMerck Gets FDA Priority Review For New Pneumococcal Vaccine
19/12/202308:45BWFDA Grants Priority Review to Merck’s New Biologics License..

Seu Histórico Recente

NYSE
MRK
Merck
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados